M. Sendur

Real-life experience with maintenance chemotherapy plus biologics after the first-line treatment of RAS wild-type metastatic colon cancer (mCRC): A multicenter Onco-Colon Turkey study

Background Randomized clinical trials showed that maintenance chemotherapy plus biologics in patients with mCRC could increase the progression free survival (PFS) withou...

O. Bozkurt ;

A. Bilici ;

M. Ozcelik ;

B. Oven ;

E. Simsek ;

C. Geredeli ;

T. Cil ;

H. Harputluoglu ;

H. Turk ;

U. Kefeli ;

A. Alacacioglu ;

D. Tural ;

Sevilay Şenol Çelik , PhD, RN;

M. Gumus ;

A. Sakin ;

M. Sendur ;

N. Karadurmus ;

M. Karaca ;

M. Artac ;

D. Cevik ;

E. Cubukcu ;

F. Dane ;

06/27/2022

Phase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high or mismatch repair-deficient stage IV colorectal cancer

Background The PD-1 inhibitor pembrolizumab has shown robust clinical activity in patients with mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H)...

M. Gumus ;

J. Bae Ahn ;

L. Wyrwicz ;

M. Kwiatkowski ;

J. Kim ;

S. Yalcin ;

M. Sendur ;

A. Odeleye-Ajakaye ;

P. Leconte ;

T. Andre ;

T. Kim ;

D. Fogelman ;